Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA4 | P22748 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 10/20 | 0.41 |
| ▸ | MAOA | P21397 | 6/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31009815 | 1.00 | CA12 (0.45) | CA12CA4CA9CA1GSTP1 | |
| SCHEMBL18761828 | 0.83 | GSTP1 (0.49) | CA12CA4CA9CA1GSTP1 | |
| SCHEMBL10963900 | 0.79 | MAOB (0.49) | CA12CA4CA9CA1GSTP1 | |
| SCHEMBL28397565 | 0.79 | GSTP1 (0.45) | CA12CA4CA9CA1GSTP1 | |
| SCHEMBL15710785 | 0.76 | NQO1 (0.50) | CA12CA4CA9CA1CA2 | |
| SCHEMBL17453941 | 0.76 | MAOB (0.33) | MAOBMAOAKDM4E | |
| SCHEMBL21718941 | 0.75 | KDM4E (0.49) | CA12CA4CA9CA1GSTP1 | |
| SCHEMBL28397137 | 0.75 | GSTP1 (0.45) | CA12CA4CA9CA1GSTP1 | |
| SCHEMBL21718842 | 0.75 | CA12 (0.41) | CA12CA4CA9CA1GSTP1 | |
| SCHEMBL9061932 | 0.74 | CA12 (0.64) | CA12CA4CA9CA1GSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583870-B2 | Azaheteroaryl compound and application thereof | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019521-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | Blueray Therapeutics (Shanghai) Co., Ltd (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021032004-A9 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| WO-2021032004-A9 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-03-25 | — | — | WO | disclosed |
| CN-112409385-A | Azaaryl compounds and uses thereof | 上海青煜医药科技有限公司 | 2021-02-26 | — | — | CN | disclosed |
| WO-2021032004-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| WO-2021032004-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | 上海青煜医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| CN-110734436-A | Pyrimidine or pyrazine ring compounds and application thereof | 上海青煜医药科技有限公司 | 2020-01-31 | — | — | CN | disclosed |
| CN-110563722-A | pyridine or pyridazine ring compound and application thereof | 上海青煜医药科技有限公司 | 2019-12-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002414-A1 | AZAHETEROARYL COMPOUND AND APPLICATION THEREOF | EZH2, EED, SUZ12 | CA12 3102/4885CA4 4409/4885CA9 3487/4885 |
| US-12583870-B2 | Azaheteroaryl compound and application thereof | NR3C1, EED, EZH2 | CA12 1604/4885CA4 2459/4885CA9 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.